Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy
Link
https://link.springer.com/content/pdf/10.1007/s11096-020-01193-z.pdf
Reference22 articles.
1. Las cifras del cáncer en España 2020. SEOM. https://seom.org/seomcms/images/stories/recursos/Cifras_del_cancer_2020.pdf. Accessed 23 Sept 2020.
2. Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013;274:113–26.
3. Gavilá J, Lopez-Tarruella S, Saura C, Muñoz M, Oliveira M, De la Cruz-Merino L, et al. SEOM clinical guidelines in metastatic breast cancer 2015. Clin Transl Oncol. 2015;17:946–55.
4. Matutino A, Joy AA, Brezden-Masley C, Chia S, Verma S. Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines. Curr Oncol. 2018;25:S131–41.
5. Zamora P, Servitja S, Santaballa A, García J, de Paz L, Plata Y, et al. Abstract P3-07-39: CASCADE study: Treatment and clinical outcomes of metastatic breast cancer by tumor immunophenotypes. In: Poster session abstracts (Internet). American Association for Cancer Research; 2016. https://doi.org/10.1158/1538-7445.SABCS15-P3-07-39. Accessed 23 Sept 2020.
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Strategy to Improve the Oral Pharmacokinetics of Cyclin-Dependent Kinase 4/6 Inhibitors: Enhancing Permeability and CYP450 Inhibition by a Natural Bioenhancer;AAPS PharmSciTech;2024-08-08
2. Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review;Tumors of female reproductive system;2024-05-17
3. Cardiovascular complications of ribociclib in breast cancer patients;Critical Reviews in Oncology/Hematology;2024-04
4. Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice;Biotechnology & Biotechnological Equipment;2023-10-19
5. Efficacy and safety of cyclin‐dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real‐world experience;Thoracic Cancer;2023-09-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3